JP2013503617A - 急性腎損傷の診断および/または予後方法 - Google Patents
急性腎損傷の診断および/または予後方法 Download PDFInfo
- Publication number
- JP2013503617A JP2013503617A JP2012527360A JP2012527360A JP2013503617A JP 2013503617 A JP2013503617 A JP 2013503617A JP 2012527360 A JP2012527360 A JP 2012527360A JP 2012527360 A JP2012527360 A JP 2012527360A JP 2013503617 A JP2013503617 A JP 2013503617A
- Authority
- JP
- Japan
- Prior art keywords
- mir
- expression
- kidney injury
- acute kidney
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000033626 Renal failure acute Diseases 0.000 title claims abstract description 65
- 201000011040 acute kidney failure Diseases 0.000 title claims abstract description 65
- 208000009304 Acute Kidney Injury Diseases 0.000 title claims abstract description 64
- 238000003745 diagnosis Methods 0.000 title claims abstract description 16
- 238000004393 prognosis Methods 0.000 title claims abstract description 16
- 230000014509 gene expression Effects 0.000 claims abstract description 125
- 239000002679 microRNA Substances 0.000 claims abstract description 66
- 108091028076 Mir-127 Proteins 0.000 claims abstract description 27
- 108091048308 miR-210 stem-loop Proteins 0.000 claims abstract description 26
- 108091028066 Mir-126 Proteins 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 20
- 108700011259 MicroRNAs Proteins 0.000 claims abstract description 18
- 210000002966 serum Anatomy 0.000 claims description 35
- 210000002700 urine Anatomy 0.000 claims description 19
- 239000013610 patient sample Substances 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 8
- 206010061481 Renal injury Diseases 0.000 claims description 7
- 208000037806 kidney injury Diseases 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 3
- 238000002493 microarray Methods 0.000 claims description 3
- 238000003753 real-time PCR Methods 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 description 66
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 65
- 239000001301 oxygen Substances 0.000 description 65
- 210000004027 cell Anatomy 0.000 description 57
- 108091070501 miRNA Proteins 0.000 description 54
- 206010021143 Hypoxia Diseases 0.000 description 39
- 235000015097 nutrients Nutrition 0.000 description 33
- 208000012998 acute renal failure Diseases 0.000 description 31
- 230000007954 hypoxia Effects 0.000 description 24
- 230000006378 damage Effects 0.000 description 17
- 230000001146 hypoxic effect Effects 0.000 description 15
- 208000028867 ischemia Diseases 0.000 description 14
- 230000000302 ischemic effect Effects 0.000 description 14
- 210000003734 kidney Anatomy 0.000 description 13
- 206010063897 Renal ischaemia Diseases 0.000 description 12
- 210000005234 proximal tubule cell Anatomy 0.000 description 12
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 10
- 206010038540 Renal tubular necrosis Diseases 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000003511 endothelial effect Effects 0.000 description 9
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 235000016709 nutrition Nutrition 0.000 description 8
- 230000035764 nutrition Effects 0.000 description 8
- 235000021232 nutrient availability Nutrition 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 208000037906 ischaemic injury Diseases 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 238000007675 cardiac surgery Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 240000008213 Brosimum alicastrum Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
- 102000003661 Ribonuclease III Human genes 0.000 description 2
- 108010057163 Ribonuclease III Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 235000005828 ramon Nutrition 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 210000005233 tubule cell Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 208000021709 Delayed Graft Function Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 244000187656 Eucalyptus cornuta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 102000013519 Lipocalin-2 Human genes 0.000 description 1
- 108010051335 Lipocalin-2 Proteins 0.000 description 1
- 108091007773 MIR100 Proteins 0.000 description 1
- 108091060568 Mir-133 microRNA precursor family Proteins 0.000 description 1
- 108091028684 Mir-145 Proteins 0.000 description 1
- 108091062140 Mir-223 Proteins 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 241000269435 Rana <genus> Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000002583 cell-derived microparticle Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108091023685 miR-133 stem-loop Proteins 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000010024 tubular injury Effects 0.000 description 1
- 208000037978 tubular injury Diseases 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
したがって、第1の態様において、本発明は、患者のサンプルを分析して、miR-127、miR-126、miR-210およびmiR-101から選ばれる少なくとも1つのマイクロRNAの発現レベルを決定し、コントロール値と該発現レベルを比較することを含む、該レベルの変化が腎損傷を示す急性腎損傷の診断および/または予後方法を提供する。
R/Iを偽装しているHRモデルにおいて、マイクロRNA:miR-127、miR-126、miR-210およびmiR-101のそれぞれが、単独あるいは組み合わせで腎損傷のバイオマーカーとして機能するようにディファレンシャル方式で(in a differential way)発現されるこれらのマイクロRNAを、アレイの使用によって同定した。
特異的血清、抗生物質および成長因子を含む適切な手段で、以下の細胞(HK2:ヒト近位尿細管細胞、NRK-52E:ラット近位尿細管細胞およびHMEC:ヒト微小血管内皮細胞)の培養を行った。細胞は、湿潤雰囲気およびCO2 5%下で37℃に維持した。
患者のサンプルを用いる研究を予想的方法で行った。適切なインフォームド・コンセントを通して患者または患者の法定代理人による承諾を得た後、そして、我々の病院の臨床研究倫理委員会による研究の承認前に、下記の患者のグループにおける移植の場合、血液および尿ならびに腎生検のサンプルを採取した。
50名の移植を受けた人々(新たに腎移植および異なる免疫抑制処方を受けた患者)からのサンプルを分析し、2つのグループに組織した:
1.即時型移植片機能を得た25名の患者
2.遅延型移植片機能を得た25名の患者
血液および尿のサンプルを、腎移植後の第1日、第7日、第15日、第30日に採取し、これらの日々において、研究対象のmiRNAの発現をqRT-PCRによって決定した。
移植された患者の場合、以下の情報を集め、決定した:
−レシピエントの特徴:年齢、性別および透析時間
−ドナーの特徴:ドナーのタイプ(脳死、心停止)、年齢、性別、血管作用薬要
−移植片の特徴:熱、冷虚血の回数および吻合の回数;HLA適合性および免疫抑制
−第2、4および12週における移植片の機能
分離した血清を遠心分離によって集め、分注し、Ramon and Cajal HospitalのBioBankの基準にしたがって保管した(固有コードを付けた匿名チューブ中、-80℃で)。
50名の患者のサンプルを分析し、以下のグループに組織した:
−IA:体外循環(ECC)を伴う計画的手術を受けた、ARF発生のリスクが低い10名の成人患者、すなわち、Thakar5システムにおいてスコアが0〜2であるか、または簡易SRI6において0〜1である患者
−IB:ECCを伴う最初の手術を受けた先天性心疾患の10名の小児患者
−II:変化した基礎腎機能を有し、Thakar5システムにおいてスコアが>5であるか、またはSRI6において≧3である、ECCを伴う計画的手術を受けた15名の成人患者
−III:正常な腎機能を有し、先のセクションと同じスコアである、ECCを伴う計画的手術を受けた15名の成人患者
−基礎となる手術前
−ICUにて開始、2時間
−手術の24時間、48時間および72時間後
−第7日(グループIAおよびIBについて任意)
Claims (12)
- 患者のサンプルを分析して、miR-127、miR-126、miR-210およびmiR-101から選ばれる少なくとも1つのマイクロRNAの発現レベルを決定し、コントロール値と該発現レベルを比較することを含む、該レベルの変化が腎損傷を示す、急性腎損傷の診断および/または予後方法。
- 分析されるサンプルが、血液、血清または尿から選ばれる、請求項1に記載の急性腎損傷の診断および/または予後方法。
- コントロール値に対する血清miR-127の発現レベルの減少が、急性腎損傷を示す、請求項1または2に記載の急性腎損傷の診断および/または予後方法。
- コントロール値に対する尿miR-127の発現レベルの増加が、急性腎損傷を示す、請求項1または2に記載の急性腎損傷の診断および/または予後方法。
- コントロール値に対する血清miR-126の発現レベルの減少が、急性腎損傷を示す、請求項1または2に記載の急性腎損傷の診断および/または予後方法。
- コントロール値に対する血清miR-210の発現レベルの増加が、急性腎損傷を示す、請求項1または2に記載の急性腎損傷の診断および/または予後方法。
- コントロール値に対する尿miR-210の発現レベルの増加が、急性腎損傷を示す、請求項1または2に記載の急性腎損傷の診断および/または予後方法。
- コントロール値に対する血清miR-101の発現レベルの増加が、急性腎損傷を示す、請求項1または2に記載の急性腎損傷の診断および/または予後方法。
- マイクロRNAの発現が、PCRによって決定される、前記請求項のいずれかに記載の急性腎損傷の診断および/または予後方法。
- マイクロRNAの発現が、定量的PCRによって決定される、前記請求項のいずれかに記載の急性腎損傷の診断および/または予後方法。
- マイクロRNAの発現が、ARNマイクロアレイによって決定される、請求項1〜8のいずれかに記載の方法。
- 前記請求項1〜11に記載の方法を行うのに必要なプローブおよびプライマーを含む、急性腎損傷の診断および/または予後のためのキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200901825A ES2363661B2 (es) | 2009-09-04 | 2009-09-04 | Método para el diagnóstico y/o pronóstico de daño renal agudo. |
ESP200901825 | 2009-09-04 | ||
PCT/ES2010/070579 WO2011027019A2 (es) | 2009-09-04 | 2010-09-03 | Metodo para el diagnostico y/o pronostico de daño renal agudo |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013503617A true JP2013503617A (ja) | 2013-02-04 |
JP2013503617A5 JP2013503617A5 (ja) | 2013-10-10 |
JP5801809B2 JP5801809B2 (ja) | 2015-10-28 |
Family
ID=43649710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012527360A Expired - Fee Related JP5801809B2 (ja) | 2009-09-04 | 2010-09-03 | 急性腎損傷の診断および/または予後方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20120172248A1 (ja) |
EP (2) | EP3029156B1 (ja) |
JP (1) | JP5801809B2 (ja) |
CN (1) | CN102575294B (ja) |
AU (1) | AU2010291137A1 (ja) |
CA (1) | CA2773054A1 (ja) |
ES (2) | ES2363661B2 (ja) |
IN (1) | IN2012DN01910A (ja) |
MX (1) | MX2012002333A (ja) |
PT (1) | PT3029156T (ja) |
RU (1) | RU2629591C2 (ja) |
WO (1) | WO2011027019A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020071518A1 (ja) * | 2018-10-04 | 2020-04-09 | 学校法人自治医科大学 | 急性腎障害特異的バイオマーカー、急性腎障害の診断方法、急性腎障害の検査用キット、動物治療方法、及び急性腎障害用医薬 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2484779A1 (en) * | 2011-02-03 | 2012-08-08 | Medizinische Hochschule Hannover | Device and method for analysis of kidney failure |
ES2414290B1 (es) * | 2011-12-15 | 2014-04-16 | Fundación Para La Investigación Biomédica Del Hospital Universitario Ramón Y Cajal | Metodo para el diagnóstico y/o pronóstico de daño renal agudo |
RU2587012C1 (ru) * | 2014-10-31 | 2016-06-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ульяновский государственный университет" | Способ прогнозирования острого повреждения почек у больных острым коронарным синдромом |
RU2583950C1 (ru) * | 2015-05-13 | 2016-05-10 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ прогнозирования развития острого повреждения почки в условиях тепловой ишемии в эксперименте в зависимости от возраста и пола животных |
RU2639465C2 (ru) * | 2016-02-24 | 2017-12-21 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ульяновский государственный университет" | Способ прогнозирования острого повреждения почек у больных острым коронарным синдромом |
WO2018033454A1 (en) * | 2016-08-19 | 2018-02-22 | Fundación Para La Investigación Biomédica Del Hospital Universitario Ramón Y Cajal | Mir-127 agents for use in the treatment of renal fibrosis |
WO2018065390A1 (en) | 2016-10-04 | 2018-04-12 | Vib Vzw | Means and methods to treat inflammatory diseases |
RU2666911C2 (ru) * | 2016-11-24 | 2018-09-13 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт общей патологии и патофизиологии" (ФГБНУ "НИИОПП") | Способ для прогнозирования метастазирования рака яичников на основе группы генов микроРНК |
TWI646199B (zh) * | 2017-10-23 | 2019-01-01 | 長庚醫療財團法人林口長庚紀念醫院 | 用於預測一帶有急性心肌梗塞的人類個體發展出急性腎損傷之風險的方法 |
RU2702023C1 (ru) * | 2018-08-17 | 2019-10-04 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ диагностики острого повреждения почек после органосохраняющего хирургического лечения локализованного рака почки |
RU2703399C1 (ru) * | 2018-11-02 | 2019-10-16 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт общей патологии и патофизиологии" (ФГБНУ "НИИОПП") | Способ для диагностики рака яичников на основе группы генов микроРНК |
RU2724017C1 (ru) * | 2019-05-17 | 2020-06-18 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ульяновский государственный университет" | Способ прогнозирования острого повреждения почек у больных острым коронарным синдромом с использованием шкалы риска |
EP3929308A1 (en) | 2020-06-23 | 2021-12-29 | Heinrich-Heine-Universität Düsseldorf | Diagnostic methods on renal recovery in individuals suffering from acute kidney injury and suitable biomarkers therefor |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7575863B2 (en) * | 2004-05-28 | 2009-08-18 | Applied Biosystems, Llc | Methods, compositions, and kits comprising linker probes for quantifying polynucleotides |
RU2270605C1 (ru) * | 2004-06-18 | 2006-02-27 | Государственное учреждение научный центр здоровья детей РАМН (ГУ НЦЗД РАМН) | Способ оценки жизнеспособности почечной паренхимы |
EP1915614A4 (en) * | 2005-07-21 | 2009-03-25 | Univ Johns Hopkins | ACUTE RENAL FAILURE |
WO2009038742A2 (en) * | 2007-09-20 | 2009-03-26 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Method for estimating risk of acute kidney injury |
-
2009
- 2009-09-04 ES ES200901825A patent/ES2363661B2/es active Active
-
2010
- 2010-09-03 IN IN1910DEN2012 patent/IN2012DN01910A/en unknown
- 2010-09-03 RU RU2012106742A patent/RU2629591C2/ru not_active IP Right Cessation
- 2010-09-03 CA CA2773054A patent/CA2773054A1/en not_active Abandoned
- 2010-09-03 JP JP2012527360A patent/JP5801809B2/ja not_active Expired - Fee Related
- 2010-09-03 WO PCT/ES2010/070579 patent/WO2011027019A2/es active Application Filing
- 2010-09-03 MX MX2012002333A patent/MX2012002333A/es active IP Right Grant
- 2010-09-03 ES ES16150622T patent/ES2710332T3/es active Active
- 2010-09-03 EP EP16150622.5A patent/EP3029156B1/en active Active
- 2010-09-03 AU AU2010291137A patent/AU2010291137A1/en not_active Abandoned
- 2010-09-03 PT PT16150622T patent/PT3029156T/pt unknown
- 2010-09-03 CN CN201080044847.XA patent/CN102575294B/zh not_active Expired - Fee Related
- 2010-09-03 US US13/394,084 patent/US20120172248A1/en not_active Abandoned
- 2010-09-03 EP EP10813383A patent/EP2474622A4/en not_active Withdrawn
Non-Patent Citations (4)
Title |
---|
JPN6014048106; PNAS Vol.106, No.13, 200903, pp.5330-5335 * |
JPN6014048107; Am. J. Physiol. Renal Physiol. Vol.297, 200908, pp.F961-F970 * |
JPN6014048109; Transplant Immunology Vol.19, 2008, pp.81-85 * |
JPN6014048111; PLOS ONE Vol.7, No.9, 2012, e44305 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020071518A1 (ja) * | 2018-10-04 | 2020-04-09 | 学校法人自治医科大学 | 急性腎障害特異的バイオマーカー、急性腎障害の診断方法、急性腎障害の検査用キット、動物治療方法、及び急性腎障害用医薬 |
JPWO2020071518A1 (ja) * | 2018-10-04 | 2021-12-02 | 学校法人自治医科大学 | 急性腎障害特異的バイオマーカー、急性腎障害の診断方法、急性腎障害の検査用キット、動物治療方法、及び急性腎障害用医薬 |
JP7166659B2 (ja) | 2018-10-04 | 2022-11-08 | 学校法人自治医科大学 | 急性腎障害の検査方法、急性腎障害の検査用キット、動物治療方法、及び急性腎障害用医薬 |
Also Published As
Publication number | Publication date |
---|---|
CN102575294A (zh) | 2012-07-11 |
EP3029156A2 (en) | 2016-06-08 |
EP2474622A1 (en) | 2012-07-11 |
EP3029156B1 (en) | 2018-11-07 |
WO2011027019A3 (es) | 2011-04-28 |
EP3029156A3 (en) | 2016-09-14 |
US20120172248A1 (en) | 2012-07-05 |
PT3029156T (pt) | 2019-02-11 |
EP2474622A4 (en) | 2013-03-06 |
ES2710332T3 (es) | 2019-04-24 |
RU2012106742A (ru) | 2013-10-10 |
MX2012002333A (es) | 2012-06-12 |
RU2629591C2 (ru) | 2017-08-30 |
WO2011027019A2 (es) | 2011-03-10 |
ES2363661A1 (es) | 2011-08-11 |
CA2773054A1 (en) | 2011-03-10 |
IN2012DN01910A (ja) | 2015-07-24 |
AU2010291137A1 (en) | 2012-03-15 |
CN102575294B (zh) | 2015-07-01 |
ES2363661B2 (es) | 2012-05-30 |
JP5801809B2 (ja) | 2015-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5801809B2 (ja) | 急性腎損傷の診断および/または予後方法 | |
Vahed et al. | Dysregulation of urinary miR-21 and miR-200b associated with interstitial fibrosis and tubular atrophy (IFTA) in renal transplant recipients | |
CA2982486C (en) | Nucleic acid markers for rapid diagnosis of kawasaki disease and kit for detection of the nucleic acid markers | |
CN107385035B (zh) | 与2型糖尿病视网膜病变相关的血清/血浆miRNA标志物及其应用 | |
US8574838B2 (en) | Methods and kits for miRNA isolation and quantitation | |
CN108179194B (zh) | 一种肿瘤分子标志物circBIRC6及其抑制剂和用途 | |
WO2020088704A1 (en) | Postpartum epigenetic profile of cardiovascular micrornas in women exposed to pregnancy-related complications | |
CN111500710A (zh) | circRNA730作为生物标志物在预测、诊断或预后脓毒症中的用途 | |
US20170175191A1 (en) | Method for the diagnosis and/or prognosis of acute renal damage | |
CN106676185B (zh) | 一种预测个体动脉瘤发生的血液中外泌体miRNA谱及检测试剂盒 | |
CN107012256A (zh) | 腹主动脉瘤诊治标志物 | |
CN111154863B (zh) | lncRNA在制备诊断和/或治疗骨关节炎的产品中的应用 | |
CN113718028A (zh) | 基于微小rna的子痫前期诊断用途及组合物 | |
WO2017068198A1 (en) | Biomarker for predicting coronary artery disease in smokers | |
CN114717318B (zh) | 一种用于脑动脉瘤早期诊断或检测的ceRNA调控网络及其应用 | |
ES2374890B1 (es) | Método para el diagnóstico y/o pronóstico de daño renal agudo. | |
CN107586845A (zh) | 胶质瘤诊断标志物Circ19:5604583|5604936及应用 | |
CN107012257A (zh) | 用于诊治腹主动脉瘤的生物标志物 | |
CN114807348B (zh) | 长链非编码rna lra-1及其干扰rna在治疗动脉粥样硬化中的应用 | |
CN108796070B (zh) | miR-125a-3p在制备心血管疾病诊断试剂盒中的用途 | |
CN116356009A (zh) | 一种miR-122-5p的应用 | |
ES2381401A1 (es) | Método para el diagnóstico y/o pronóstico de daño renal agudo. | |
ALSHAWADFI et al. | MICRORNA UTILITY FOR DIAGNOSING ISCHEMIC STROKE IN EGYPTIAN PATIENTS | |
PL241808B1 (pl) | Zastosowanie markerów mikroRNA do wykrywania obecności tętniaków aorty brzusznej oraz sposób diagnozowania tętniaków aorty brzusznej | |
Ohlow et al. | P2577 Predictors of long-term outcome in patients with biopsy proven inflammatoric cardiomyopathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130820 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130820 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150126 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150602 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150605 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150804 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150827 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5801809 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |